Background and purpose The Mynx M5 (AccessClosure, Inc., Mountain View, California, USA), a novel vascular closure device (VCD) utilizing extravascular synthetic sealant, may effectively seal the arteriotomy while reducing the pain associated with arteriotomy closure seen with other VCDs. To date, no studies exist comparing the pain associated with deployment between differing VCDs as a primary end point.
Methods A blinded, randomized controlled trial was performed comparing the Mynx and a popular VCD that utilizes a self-tightening suture, the Angio-Seal Evolution (St Jude Medical, St Paul, Minnesota, USA). Subjects were all adult patients undergoing diagnostic cerebral angiography via femoral access. Local anesthesia and intraprocedural intravenous pain medication were standardized. Pain was assessed using a horizontal visual analog scale both before and after VCD deployment.
Results 64 patients were enrolled with 32 in each treatment arm. Both pain at closure and pain increase from baseline to closure were significantly higher in the Angio-Seal group (p=0.009 and 0.002, respectively). 88% of patients receiving an Angio-Seal reported closure as the most painful part of the procedure compared with only 34% of patients receiving the Mynx (p<0.001). No adverse events were detected in either treatment arm.
Conclusions In a blinded, randomized trial comparing the Mynx with the Angio-Seal Evolution, pain with device deployment at arteriotomy closure was significantly lower with the Mynx. The reason for the large pain gradient between groups is likely due to the presence, and absence, of compression elements within the Angio-Seal and Mynx, respectively.
Statistics from Altmetric.com
Disclosures All authors (Fargen, Hoh, Mocco) participated in manuscript composition, data collection/analysis, clinical care and/or critical review of the manuscript. All ethical guidelines have been adhered to in the composition of this work. It is not under consideration for publication in any other journal. The University of Florida receives an educational grant and consulting fees from Codman Neurovascular. Dr Mocco serves on the Clinical Events Committee Adjudication Board for the Conscious-2 and Conscious-3 International Studies (Actelion, Inc). He is a consultant for Nfocus and Lazarus Effect and receives honoraria from Edge Therapeutics. Dr Hoh receives honoraria from Codman Neurovascular and Actelion Inc. as well as non-financial research support from Micrus Endovascular. This study was funded in part by a scientific research grant from Access Closure, Inc., however, this was an independently run physician-initiated study, and Access Closure, Inc. had no input into data collection, analysis or presentation.
Funding This study was funded in part by a scientific research grant from Access Closure, Inc., however, this was an independently run physician-initiated study, and Access Closure, Inc. had no input into data collection, analysis or presentation.
Competing interests None.
Ethics approval This study was conducted with the approval of the University of Florida Institutional Review Board, as stated in the article.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.